Commonwealth Equity Services
CSTL icon

Commonwealth Equity Services’s Castle Biosciences CSTL Stock Holding History

Commonwealth Equity Services’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,591
Closed -$256K – 4339
2025
Q4 		$256K Buy
+6,591
New +$212K ﹤0.01% 3783
2023
Q4 		– Sell
-11,274
Closed -$190K – 3931
2023
Q3 		$190K Sell
11,274
-4,022
-26% -$70.3K ﹤0.01% 3399
2023
Q2 		$210K Buy
+15,296
New +$310K ﹤0.01% 3362
2022
Q2 		– Sell
-4,603
Closed -$206K – 3693
2022
Q1 		$206K Buy
+4,603
New +$190K ﹤0.01% 3315
2021
Q4 		– Sell
-5,071
Closed -$337K – 3666
2021
Q3 		$337K Sell
5,071
-6
-0.1% -$422 ﹤0.01% 2802
2021
Q2 		$372K Buy
5,077
+1,200
+31% +$79.3K ﹤0.01% 2717
2021
Q1 		$265K Buy
+3,877
New +$291K ﹤0.01% 2886

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Commonwealth Equity Services's CSTL Position: Q1 2026 in Review

Commonwealth Equity Services sold out of Castle Biosciences (CSTL) in Q1 2026, closing a stake of 6,591 shares — an estimated $256K sold.

Commonwealth Equity Services first reported a position in CSTL in Q1 2021 and held it in 7 quarters. The position peaked at $372K in Q2 2021. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Commonwealth Equity Services reported no remaining Castle Biosciences position as of Q1 2026 after selling out during the quarter.
  • Commonwealth Equity Services sold 6,591 Castle Biosciences shares in Q1 2026, an estimated $256K.
  • Commonwealth Equity Services first reported a position in Castle Biosciences in Q1 2021 and held it in 7 quarters.
  • Commonwealth Equity Services's Castle Biosciences position peaked at $372K in Q2 2021.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Commonwealth Equity Services's 13F filing for Q1 2026, filed 27 Apr 2026.